ACTIVE

Hirundo Biosciences

Export PDF

Financial year 2025 · Closed on 31/12/2025

Net result-13,7 M €-987,6 %over 1 year
Revenue0 €-100,0 %over 1 year
Equity-548,2 k €-130,6 %over 1 year
Workforce12,2 ETP+351,9 %over 1 year

Identity

Source · BCE/KBO

Hirundo Biosciences is a Public limited company incorporated in 2017. Its main activity is: Buying and selling of own real estate. Its registered office is in Liège. It employs on average 12,2 ETP workers (FTE).

Legal situation
Normal situation
BCE/KBO no. / VAT
BE 0681.855.065
Incorporation
28/09/2017
Legal form
Public limited company
Registered office
Boulevard de Patience et Beaujonc 3
4000 Liège · WallonieSee on map
Contributed capital
1 468 649,92 €
Latest accounts
31/12/2025
Average workforce
12,2 ETP
Joint committees (1)
  • 207

Financials

Source · NBB, 8 filings

Trend over 8 financial years

20252024202320222021
Income statement
Revenue0 €277,7 k €–––
EBITDA-4,1 M €-86,2 k €498,6 k €140,8 k €733,3 k €
Operating result-8,7 M €-1,3 M €-409,5 k €-998,6 k €-208,1 k €
Net result-13,7 M €-1,3 M €-347,1 k €-1 M €-210,8 k €
Balance sheet
Equity-548,2 k €1,8 M €3,1 M €3,4 M €4,4 M €
Total assets3,4 M €6,9 M €5,8 M €5,9 M €6 M €
Cash––74 k €220,6 k €335,9 k €
Debts3,9 M €5,1 M €2,5 M €2,4 M €1,4 M €
Other
Workforce12,2 ETP2,7 ETP2,0 ETP2,8 ETP3,0 ETP

Board of directors

Source · NBB, accounts to 31/12/2025

3 active · 28 ended

Active mandates

András Kovács Lászlò

Director · since 25 avril 2025 · until 06 juin 2030

Active
Istvàn Greiner

Director · since 19 juin 2024 · until 06 juin 2030

Active
Péter Turek

Director · since 19 juin 2024 · until 06 juin 2030

Active

Ended mandates

Lászlò András Kovács

Director · since 25 avril 2025 · until 06 juin 2030

Ended
Istvan Hamecz

Director · since 19 juin 2024 · until 25 avril 2025

Ended
ACCESS & PARTNERS

Director · since 01 juin 2023 · until 18 juin 2024 · 0452.367.319

Represented by Didier Malherbe

Ended
ACCESS & PARTNERS

Director · since 01 juin 2023 · until 07 juin 2029 · 0452.367.319

Represented by Didier MALHERBE

Ended

Other companies at this address

Boulevard de Patience et Beaujonc 3 4000 Liège
CompanyCBE no.
Abscint● Active
0749.828.410
AMPACIMON● Active
0827.990.317
Amyl Therapeutics● Active
0758.775.372
BECARV● Bankrupt
0840.777.885
BE.SPINE● Active
1013.110.857
CEFALY Technology● Active
0870.578.661
DERMAX● Active
0667.730.677
DIANOSIC● Active
1034.558.646
DW Cefaly Holding● Active
0725.837.241
EARTH ALIVE CLEAN TECHNOLOGIES BELGIUM● Active
1023.778.481
EXO Biologics● Active
0732.982.379
ExoXpert● Active
1003.807.666
HolyFox Invest● Active
1010.693.181
Hyloris● Active
0669.738.676
Hyloris Developments● Active
0542.737.368
Hyloris Pharmaceuticals● Active
0674.494.151
Hyloris Therapeutics● Active
1025.029.385
LEGIAPARK● Active
0728.589.170
MAN & SCIENCE● Active
0837.403.770
ONCORADIOMICS● Active
0662.719.440

Full financial information

Source · NBB
202520242023202220212020
Type of accountAbridged modelAbridged modelAbridged modelAbridged modelAbridged modelAbridged model
Start of the financial year01/01/202501/01/202401/01/202301/01/202201/01/202101/01/2020
Closing of the financial year31/12/202531/12/202431/12/202331/12/202231/12/202131/12/2020
Length of the financial year12 months12 months12 months12 months12 months12 months
Filing date24/07/202608/08/202521/08/202426/07/202331/08/202209/08/2021
General meeting04/06/202623/07/202506/06/202408/06/202302/06/202203/06/2021
Currency of the financial yearEUREUREUREUREUREUR
NBB quality labelSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for 7 days

Annual accounts filings

Source · NBB, 8 filings
ModelClosingGeneral meetingFiledLanguageDocument
Abridged model31/12/202504/06/202624/07/2026FrenchPDF
Abridged model31/12/202423/07/202508/08/2025FrenchPDF
Abridged model31/12/202306/06/202421/08/2024FrenchPDF
Abridged model31/12/202208/06/202326/07/2023FrenchPDF
Abridged model31/12/202102/06/202231/08/2022FrenchPDF
Abridged model31/12/202003/06/202109/08/2021FrenchPDF
Abridged model31/12/201904/06/202003/08/2020FrenchPDF
Micro model31/12/201806/06/201904/07/2019FrenchPDF

Indicative valuation

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2025

3 active · 28 ended

Active mandates

András Kovács Lászlò

Director · since 25 avril 2025 · until 06 juin 2030

Active
Istvàn Greiner

Director · since 19 juin 2024 · until 06 juin 2030

Active
Péter Turek

Director · since 19 juin 2024 · until 06 juin 2030

Active

Ended mandates

Lászlò András Kovács

Director · since 25 avril 2025 · until 06 juin 2030

Ended
Istvan Hamecz

Director · since 19 juin 2024 · until 25 avril 2025

Ended
ACCESS & PARTNERS

Director · since 01 juin 2023 · until 18 juin 2024 · 0452.367.319

Represented by Didier Malherbe

Ended
ACCESS & PARTNERS

Director · since 01 juin 2023 · until 07 juin 2029 · 0452.367.319

Represented by Didier MALHERBE

Ended

Ownership and network

Looking for more information about this company?

Try for 7 days

Belgian Official Gazette publications

Source · Belgian Official Gazette
  • Other24/06/2026
    DIVERS
    PDF
  • Capital / shares26/01/2026
    STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, …) - CAPITAL, ACTIONS
    PDF
  • Registered office15/12/2025
    DIVERS - SIEGE SOCIAL
    PDF
  • Mandates22/07/2025
    STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, …) - DENOMINATION - CAPITAL, ACTIONS
    PDF
  • Mandates03/06/2025
    DEMISSIONS, NOMINATIONS
    PDF
  • Mandates24/04/2025
    DEMISSIONS, NOMINATIONS
    PDF
  • Mandates02/09/2024
    CAPITAL, ACTIONS - DEMISSIONS, NOMINATIONS
    PDF
  • Mandates07/08/2024
    DEMISSIONS, NOMINATIONS
    PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

  1. 2025
    Annual accounts 2025-13,7 M €↓
  2. 2024
    Annual accounts 2024-1,3 M €↓
  3. 2024
    Name changeHirundo Biosciences
  4. 2023
    Annual accounts 2023-347,1 k €↑
  5. 2022
    Annual accounts 2022-1 M €↓
  6. 2021
    Annual accounts 2021-210,8 k €↑
  7. 2021
    Name changeB.C.I. PHARMA
  8. 2020
    Annual accounts 2020-463,3 k €↑
  9. 2019
    Annual accounts 2019-1,2 M €↓
  10. 2018
    Annual accounts 2018-720,2 k €
  11. 28/09/2017
    IncorporationPublic limited company